VU0357017 hydrochloride

• CAT Number: I000509
• CAS Number: 1135242-13-5
• Molecular Formula: C18H27N3O3 • HCl
• Molecular Weight: 369.90
• Purity: ≥95%
• Synonyms: ethyl 4-((2-(2-methylbenzamido)ethyl)amino)piperidine-1-carboxylate hydrochloride
• Target: Neuronal Signaling
• Solubility: DMSO: ≥ 33 mg/mL
• Storage: Store at +4C
• IC50: 477 ± 172 nM (EC50)
• IUPAC Name: ethyl 4-[2-[(2-methylbenzoyl)amino]ethylamino]piperidine-1-carboxylate;hydrochloride
• InChI: InChI=1S/C18H27N3O3.ClH/c1-3-24-18(23)21-12-8-15(9-13-21)19-10-11-20-17(22)16-7-5-4-6-14(16)2;/h4-7,15,19H,3,8-13H2,1-2H3,(H,20,22);1H
• InChIKey: XKJQVUIXSBOCPP-UHFFFAOYSA-N
• SMILES: CCOC(=O)N1CCC(CC1)NCCNC(=O)C2=CC=CC=C2C.Cl

VU0357017 hydrochloride（Cat No.:I000509）is a selective antagonist of the G protein-coupled receptor (GPCR) GPR52, a receptor implicated in neurodegenerative diseases and psychiatric disorders. GPR52 is involved in the regulation of dopaminergic signaling, and its dysregulation has been linked to conditions such as schizophrenia and Parkinson’s disease. By inhibiting GPR52, VU0357017 hydrochloride is being explored for its potential to modulate brain function and treat psychiatric disorders. Preclinical studies suggest that targeting GPR52 may help improve cognitive function and alleviate symptoms of neuropsychiatric diseases, making it a promising candidate for further clinical development.